Eli Lilly’s Danish entry boosts market competition

Eli Lilly’s introduction of the diabetes and weight loss drug Mounjaro to Denmark is expected to increase competition in the treatment of severe obesity, benefitting patients with more treatment options. Søren Løntoft Hansen, a senior analyst at Sydbank, believes Mounjaro presents a viable alternative to Novo Nordisk’s products Ozempic and Wegovy. The launch will place Eli Lilly in direct competition with Novo Nordisk on its home turf; however, given the relative size of the Danish market, it’s unlikely to significantly shake Novo Nordisk’s strong position. Hansen is eager to see how Mounjaro is received by both patients and prescribing doctors, emphasizing the role of doctors’ familiarity with medications, as well as pricing and subsidy conditions, in its adoption.